These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 11895913)

  • 1. The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer.
    Sjöström J; Blomqvist C; von Boguslawski K; Bengtsson NO; Mjaaland I; Malmström P; Ostenstadt B; Wist E; Valvere V; Takayama S; Reed JC; Saksela E
    Clin Cancer Res; 2002 Mar; 8(3):811-6. PubMed ID: 11895913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients?
    Kymionis GD; Dimitrakakis CE; Konstadoulakis MM; Arzimanoglou I; Leandros E; Chalkiadakis G; Keramopoulos A; Michalas S
    J Surg Res; 2001 Aug; 99(2):161-8. PubMed ID: 11469882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The expression of p53, bcl-2, bax, fas and fasL in the primary tumour and lymph node metastases of breast cancer.
    Sjöström-Mattson J; Von Boguslawski K; Bengtsson NO; Mjaaland I; Salmenkivi K; Blomqvist C
    Acta Oncol; 2009; 48(8):1137-43. PubMed ID: 19863221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma.
    Krajewski S; Blomqvist C; Franssila K; Krajewska M; Wasenius VM; Niskanen E; Nordling S; Reed JC
    Cancer Res; 1995 Oct; 55(19):4471-8. PubMed ID: 7671262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.
    Buchholz TA; Garg AK; Chakravarti N; Aggarwal BB; Esteva FJ; Kuerer HM; Singletary SE; Hortobagyi GN; Pusztai L; Cristofanilli M; Sahin AA
    Clin Cancer Res; 2005 Dec; 11(23):8398-402. PubMed ID: 16322301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
    Linjawi A; Kontogiannea M; Halwani F; Edwardes M; Meterissian S
    J Am Coll Surg; 2004 Jan; 198(1):83-90. PubMed ID: 14698315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of Bcl-2 family proteins in advanced laryngeal squamous cell carcinoma: correlation with response to chemotherapy and organ preservation.
    Trask DK; Wolf GT; Bradford CR; Fisher SG; Devaney K; Johnson M; Singleton T; Wicha M
    Laryngoscope; 2002 Apr; 112(4):638-44. PubMed ID: 12150516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
    Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L
    Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of apoptosis in synovial sarcoma: correlation with clinicopathologic parameters, cell proliferative activity, and expression of apoptosis-related proteins.
    Kawauchi S; Fukuda T; Oda Y; Saito T; Oga A; Takeshita M; Yokoyama K; Chuman H; Iwamoto Y; Sasaki K; Tsuneyoshi M
    Mod Pathol; 2000 Jul; 13(7):755-65. PubMed ID: 10912935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FAS/FAS ligand ratio: a marker of oxaliplatin-based intrinsic and acquired resistance in advanced colorectal cancer.
    Nadal C; Maurel J; Gallego R; Castells A; Longarón R; Marmol M; Sanz S; Molina R; Martin-Richard M; Gascón P
    Clin Cancer Res; 2005 Jul; 11(13):4770-4. PubMed ID: 16000573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy.
    Parton M; Krajewski S; Smith I; Krajewska M; Archer C; Naito M; Ahern R; Reed J; Dowsett M
    Clin Cancer Res; 2002 Jul; 8(7):2100-8. PubMed ID: 12114409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil.
    Tahara M; Ochiai A; Fujimoto J; Boku N; Yasui W; Ohtsu A; Tahara E; Yoshida S
    Oncol Rep; 2004 Jan; 11(1):9-15. PubMed ID: 14654896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of Bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy.
    Yang Q; Sakurai T; Yoshimura G; Suzuma T; Umemura T; Nakamura M; Nakamura Y; Mori I; Kakudo K
    Oncol Rep; 2003; 10(1):121-5. PubMed ID: 12469156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
    Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
    Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunofluorometric study of Bcl-2 and Bax expression in clinical fresh tumor samples from breast cancer patients.
    Martínez-Arribas F; Núñez-Villar MJ; Lucas AR; Sánchez J; Tejerina A; Schneider J
    Anticancer Res; 2003; 23(1B):565-8. PubMed ID: 12680147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2.
    Schuyer M; van der Burg ME; Henzen-Logmans SC; Fieret JH; Klijn JG; Look MP; Foekens JA; Stoter G; Berns EM
    Br J Cancer; 2001 Nov; 85(9):1359-67. PubMed ID: 11720475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Image cytometric bcl-2:bax and bcl-2:bcl-x ratios in invasive breast carcinoma: correlation with prognosis.
    Schiller AB; Clark WS; Cotsonis G; Lawson D; DeRose PB; Cohen C
    Cytometry; 2002 Aug; 50(4):203-9. PubMed ID: 12210599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
    Geisler S; Lønning PE; Aas T; Johnsen H; Fluge O; Haugen DF; Lillehaug JR; Akslen LA; Børresen-Dale AL
    Cancer Res; 2001 Mar; 61(6):2505-12. PubMed ID: 11289122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients.
    Kariya S; Ogawa Y; Nishioka A; Moriki T; Ohnishi T; Ito S; Murata Y; Yoshida S
    Radiat Med; 2005 May; 23(3):189-94. PubMed ID: 15940066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.